An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
Price : $35 *
At a glance
- Drugs Trametinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 26 Mar 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 01 Mar 2015 Status changed from completed to recruiting as reported by ClinicalTrials.gov.
- 26 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov